Inspire Medical Systems, Inc. (NYSE: INSP) declared Monday that it has inked a distribution agreement with Japan Lifeline Co., Ltd. (JLL). The deal has been signed to market Inspire Therapy in Japan. Japan is deemed as one of the biggest markets for medical technologies all around the globe. Both the firms have inked a deal after successful execution of reimbursement evaluation of Inspire therapy by MLHW.
Furthermore, Inspire and JLL is planning to join forces with the MHLW in order to push forward the reimbursement application for Inspire therapy, which was authorized by a specialist panel this month. The formal listing of Inspire therapy is the final step before the training of centers and physicians in Japan.
Additionally, Inspire therapy got regulatory authorization in Japan in 2018. It has disclosed that the official listing of Inspire therapy is the last step before the training of facilities and doctors in Japan. Inspire revealed that it is endeavoring to offer the sufferers and doctors in Japan a clinically supported therapy option for mild to acute OSA.
Inspire therapy is backed by solid proof and years of clinical experience showing the effectiveness and safety of its therapy. Through its deal with JLL, Inspire therapy can tackle the substantial unfulfilled need in the cure of OSA sufferers in Japan. Recently, data disclosed that nearly 9 million Japanese have an Apnea-Hypopnea Index (AHI) of more than 15, which marks them at least as mild OSA sufferers.